We previously demonstrated that MELK is abundantly expressed in GBM with preferential expression in GSCs and that targeting MELK-mediated pathways disrupt cell cycle progression of GSCs in vitro and tumor growth in vivo, suggesting that MELK is a clinically relevant molecular target for GBM therapy [10], [14]–[17]. Here, MELK is linked to neoplasm.